Studies

Question 1

What are the major RT dose escalation trials?

Answer 1

MRC RT01
Dutch CKVO96-10
PROG 9509
MD Anderson (Kuban)

Question 2

What are the trials that examine short term ADT + RT vs. RT alone?

Answer 2

TROG 96.01
D'Amico 
RTOG 9408
Quebec L-101
RTOG 8610

Question 3

What are the trials that examine long term ADT + RT vs. RT alone?

Answer 3

RTOG 8531
EORTC 22863
Quebec L-101
Casodex EPC

Question 4

Arms for TROG 9601?

Answer 4

RCT comparing 3 VS 6 MO ADT VS RT ALONE

Question 5

What are the trials that examine neoadjuvant ADT vs. adjuvant?

Answer 5

RTOG 9413

Question 6

Arms for RTOG 8531?

Answer 6

RT Alone vs. RT + ADT until progression

Question 7

Arms for CASODEX EPC trial?

Answer 7

RT Alone vs. RT + antiandrogen until progression

Question 8

What trials evaluated duration of ADT with RT?

Answer 8

RTOG 9202
Quebec L-200
Canadian trial 
TROG 96.01
EORTC 22961
ICORG 97.01
PCS IV

Question 9

SPCG-7 CATEGORY

Answer 9

RCT LONG TERM ADT WITH FLUTAMIDE +/- EBRT

Question 10

Studies evaluating pelvic nodal RT vs. no pelvic nodal RT?

Answer 10

RTOG 7706
GETUG 01
RTOG 9413

Question 11

Current RCTs examining adjuvant and salvage RT?

Answer 11

RADICALs
GETUG-1
RAVES

Question 12

RCT examining adjuvant RT +/- casodex?

Answer 12

RTOG 9601

Question 13

EUROPEAN STUDY RCT EXAMINING ADJUVANT RT VS. OBS

Answer 13

EORTC 22911

Question 14

GERMAN RECT EXAMINING ADJUVANT RT VS. OBS?

Answer 14

GERMAN ARO 96-02

Question 15

RCT examining 3 vs 10 mo ADT +RT vs. RT alone?

Answer 15

Quebec L-101

Question 16

University of Calgary RCT major results?

Answer 16

Cryotherapy vs. RT

7 year bF 27% vs. 32%, NS
5 year OS 90% vs. 88%, NS

Question 17

University of Calgary RCT toxicity results?

Answer 17

Cryotherapy vs. RT

G3-4 GU 9% vs. 6%, NS
G3-4 GI 3% vs. 7%, NS

Sexual potency 4% vs. 26%, SS

Question 18

University of Calgary inclusion criteria?

Answer 18

cT2-3 N0
PSA < 20
Prostate volume < 60 cc
***PLND if GS 8+

Question 19

EORTC 22911 inclusion criteria

Answer 19

75 yo or less
pT3a or b or positive margin
Undectable PSA was not required

Question 20

In EORTC 22911 what percentage of patients had a PSA > 0.2?

Answer 20

29.9%

Question 21

EORTC 22911 arms?

Answer 21

Adjuvant radiation vs. observation

Question 22

EORTC 22911 10 year locoregional relapse rate?

Answer 22

OBS vs. ADJ RT

16% vs. 7.3%, SS

Question 23

EORTC 22911 major 10 year findings?

Answer 23

OBS vs. ADJ RT

bPFS 41% vs. 61%, SS
OS 80% vs. 76%, NS

Question 24

EORTC 22911 RT details

Answer 24

PORT 60 Gy at 2 Gy/fx
Cone down at 50 Gy was done
No pelvic nodal RT

Question 25

EORTC 22911 PEP

Answer 25

Biochemical failure defined as PSA > 0.2 measured on two separate occurrences

Question 26

EORTC 22911 10 year toxicity

Answer 26

OBS vs. ADJ RT G3 GU 2.5% vs. 5.3%, SS G2-3 GI 2.5% vs. 1.9%, NS

Question 27

ARO 9602 inclusion criteria

Answer 27

After RP for PC: pT3-4 with +/- margins Undetectable PSA after RP 75 years or less

Question 28

RTOG 9202 inclusion criteria?

Answer 28

1. T2c-T4 | 2. PSA < 150

Question 29

RTOG 9202 arms?

Answer 29

1. RT to 65-70 Gy + CADT for 4 months for flutimide and goserelin 2. RT + CADT for 4 months and for an additional 2 years with goserelin alone

Question 30

RTOG 9202 subgroup results for patients with GS 8-10 disease?

Answer 30

LT ADT improved with SS 1. DFS (9% vs. 21%), SS 2. DSS (66% vs. 80%), SS 3. Local progression (27% vs. 17%), SS 4. DM 40% vs. 25%, SS 5. Biochemical failure 73% vs. 55%, SS 6. OS 31% vs, 45%, SS

Question 31

According to Brenner et al using data from SEER what is the risk of prostate radiation causing secondary cancers?

Answer 31

1/70 at 10 years, 1.4%

Question 32

What was the purpose of Lawton's 2005 RJ publication focusing on node positive patients from RTOG 8531?

Answer 32

RT vs. RT + immediate ADT and its impact on OS, bPFS, DM and local control

Question 33

In Lawton's 2005 RJ publication focusing on node positive patients from RTOG 8531, in patients treated with RT alone vs. RT + ADT what was 10 year OS? biochemical control? FFDM?

Answer 33

RT + ADT vs. RT Alone bPFS: 35% vs. 5%, SS FFDM: 67% vs. 52%, SS OS: 47% vs. 31%, NS

Question 34

In Lee et al 1994, Urology publication following 71 patients with pathologically positive nodes treated with RT alone, what was the 10 year OS, LC, and DM?

Answer 34

``` 10 year LC: 45% DM: 82% RFS: 10% CSS: 25% OS: 20% ```

Question 35

Which study compared early vs. delayed ADT alone for clinically node positive patients?

Answer 35

EORTC 30846

Question 36

What was the median OS for patients receiving immediate ADT for clinically node positive prostate cancer in EORTC 30846?

Answer 36

7.6 years

Question 37

What was the 10 year PCSM for patients receiving immediate ADT for clinically node positive prostate cancer in EORTC 30846?

Answer 37

57% at 10 years

Question 39

What trials examined the question of long term ADT + RT. vs RT alone?

Answer 39

Casodex EORTC 22961 RTOG 8531 EORTC 22863